Asian Pacific Journal of Tropical Biomedicine

469-480

Authors: Siti Mariam A. Lathiff, Norzafneza M Arriffin, Shajarahtunnur Jamil

This article aims to review the scientific data on phytochemical and pharmacological studies of Artocarpus collected from Malaysia as well as to highlight their usage as ethnomedicine worldwide. About 55 Artocarpus species are distributed worldwide and 32 of the Artocarpus species can be found in Malaysia. Artocarpus species are well known worldwide for their edible fruits such as Artocarpus heterophyllus (jackfruit), Artocarpus integer (chempedak), and Artocarpus communis (breadfruit). Aside from its edible fruits, the timber is valued for light constructions, crates, large canoes, and boats. The literature for this review was searched using the term ‘Artocarpus’, ‘Artocarpus Malaysia’, ‘Artocarpus extracts’, ‘Artocarpus traditional medicine’ and ‘Artocarpus ethnomedicine’ from published books and scientific journals via various engines such as The Web of Science, PubMed, Science Direct, Scopus, Research Gate, and Google Scholar. The references cited from the retrieved articles were also scanned and cross-checked. All published studies on phytochemical and pharmacological activities of Malaysia’s Artocarpus species up to January 2021 were included in this review. Articles on phytochemical studies of Malaysia’s Artocarpus revealed the isolation of flavonoids as the major constituents. Research on pharmacological activities of the isolated phytochemicals showed that these compounds exhibited significant disease-linked-enzyme (tyrosinase, cholinesterase, glucosidase) inhibitors as well as antioxidant, anti-inflammatory, antimicrobial, and cytotoxic activities. The ethnomedicinal data gathered are useful to understand and prioritize Artocarpus species that can contribute to potent phytochemicals and possibly new drug leads. This review also provides valuable information for the future development of isolated compounds from Artocarpus species.

491-499

Authors: Sahar M Jaffal, Sawsan A Oran, Mohammad I Alsalem

Objective: To explore the anti-inflammatory and antipyretic effects of methanolic leaf extract from Arbutus andrachne and its mechanism of action. Methods: Paw edema was induced by intraplantar (i.pl.) injection of λ-carrageenan (1% w/v, 100 μL/paw) while pyrexia was evoked by intraperitoneal (i.p.) injection of 20% baker’s yeast (20 mL/kg body wt) in male Wistar rats. The anti-inflammatory and antipyretic effects of Arbutus andrachne methanolic leaf extract were explored by injecting rats with different doses of the plant extract (150, 300, and 600 mg/kg body wt, i.p.). Selective antagonists for transient receptor potential vanilloid-1 (TRPV1), cannabinoid receptor 1 (CB1), and alpha-2 adrenergic receptor (a2-AR) were used to unravel the extracts’ mechanism of action. Blood samples were collected from the heart of rats to measure the levels of interleukin-6 (IL-6) and prostaglandin E2 (PGE2) by enzyme-linked immunosorbent assay. Results: The extract exhibited potent anti-inflammatory activity by decreasing paw thickness and IL-6 levels. In addition, yeast-evoked pyrexia was attenuated by the extract treatment via TRPV1 and CB1 receptors and a reduction in PGE2 levels. No significant effects were found for a2-AR. Moreover, the rats that received the plant extract demonstrated similar responses to the positive control group. Conclusions: Arbutus andrachne can be a good candidate for treating inflammation and pyrexia and should be further investigated.

510-518

Authors: Hitendra S Mahajan, Nayana D Patil

Objective: To characterize a nanoemulsion containing a synergistic combination of curcumin (CUR) and quercetin (QUE) for brain targeting through the nose. Methods: The synergistic activity of the combination of two phytoconstituents, curcumin and quercetin (CUR-QUE) was determined at a 2:1 ratio. Nanoemulsions containing the synergistic combination were prepared using high-pressure homogenization technique. Nanoemulsion formulation was characterized for globule size, drug content, thermodynamic stability, zeta potential measurement, and drug release. Histological studies were performed using isolated nasal mucosa of sheep. Moreover, in vivo studies using allograft model were performed. Results: CUR-QUE in a 2:1 ratio combination showed the lowest combination index values 0.99 (combination index<1) for treatment of human glioblastoma U373-MG cell. The combination inhibited the growth of human glioblastoma U373MG cells. The significant drug targeting efficiency percentage (178.25±2.86 for CUR and 170.54±6.11 for QUE) and nose to brain drug direct transport percentage (44.05±0.93 for CUR and 38.25±0.83 for QUE) of optimized nanoemulsion (F9) indicated effective central nervous system targeting via the intranasal route. In vivo anticancer study using allograft model of nude mice demonstrated potential anticancer activity of the synergistic combination of CUR-QUE as compared to doxorubicin. Conclusions: This study demonstrates that synergistic combination of CUR-QUE was optimal for treatment of human glioblastoma. Moreover, significant site-specific delivery to the brain was achieved by administering nanoemulsion through the nose. The study also reveals that intranasal delivery of nanoemulsion containing synergistic combination of CUR and QUE could be a promising strategy for brain tumor treatment.